Mar.30.2022
R & D
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
This material is intended to notify the press release issued on March 29 (local time) by BristolMyers Squibb, our license partner for Opdivo.
Please click https://www.bms.com/media/press-releases.html for the original press release.